Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450623 | 1.00 | ALDH1A1 (0.65) | ALDH1A1HSD17B10ATAD2ACE2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3381632 | 0.98 | ALDH1A1 (0.62) | ALDH1A1HSD17B10ATAD2ACE2L3MBTL1 | |
| Pyridine SCHEMBL27788673 | 0.86 | ALDH1A1 (0.74) | ALDH1A1HSD17B10ATAD2ACE2L3MBTL1 | |
| SCHEMBL15364728 | 0.82 | IMPDH2 (0.51) | ALDH1A1HSD17B10ATAD2ACE2L3MBTL1 | |
| SCHEMBL30708901 | 0.82 | NOTUM (0.63) | ALDH1A1HSD17B10ATAD2IMPDH2NOTUM | |
| SCHEMBL4032281 | 0.82 | NOTUM (0.63) | ALDH1A1HSD17B10ATAD2IMPDH2NOTUM | |
| SCHEMBL6480845 | 0.82 | ALDH1A1 (0.83) | ALDH1A1HSD17B10L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL8115984 | 0.80 | IMPDH2 (0.59) | ALDH1A1HSD17B10ATAD2ACE2IMPDH2 | |
| Hydrochloric Acid SCHEMBL29427302 | 0.80 | ALDH1A1 (0.90) | ALDH1A1HSD17B10ATAD2L3MBTL1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15571781 | 0.80 | ALDH1A1 (0.90) | ALDH1A1HSD17B10ATAD2L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107417734-B | A kind of platinum complex and its preparation method and application with two-Photon Absorption Properties | 中山大学 | 2019-08-20 | — | — | CN | claimed |
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | claimed |
| EP-3689867-B1 | COMPOSITION, ORGANIC SEMICONDUCTOR LAYER AND ELECTRONIC DEVICE | NOVALED GMBH (DE) | 2021-12-15 | — | — | EP | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| WO-2020157204-A1 | COMPOSITION, ORGANIC SEMICONDUCTOR LAYER AND ELECTRONIC DEVICE | NOVALED GMBH (DE) | 2020-08-06 | — | — | WO | disclosed |
| EP-3689867-A1 | COMPOSITION, ORGANIC SEMICONDUCTOR LAYER AND ELECTRONIC DEVICE | Novaled GmbH (DE) | 2020-08-05 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3643720-A1 | ORGANIC COMPOUNDS, ORGANIC SEMICONDUCTOR LAYER AND ORGANIC ELECTRONIC DEVICE | Novaled GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2020016233-A1 | COMPOUND AND ORGANIC SEMICONDUCTING LAYER, ORGANIC ELECTRONIC DEVICE, DISPLAY DEVICE AND LIGHTING DEVICE COMPRISING THE SAME | NOVALED GMBH (DE) | 2020-01-23 | — | — | WO | disclosed |
| CN-107417734-B | A kind of platinum complex and its preparation method and application with two-Photon Absorption Properties | 中山大学 | 2019-08-20 | — | — | CN | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| CN-1309638-A | N-substituted naphthamides as neurokinin receptor antagonists | ASTRAZENECA AB (SE) | 2001-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | ALDH1A1 2165/4885HSD17B10 1468/4885ATAD2 234/4885 |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | ALDH1A1 1319/4885HSD17B10 839/4885ATAD2 3955/4885 |
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | ALDH1A1 423/4885HSD17B10 2357/4885ATAD2 2307/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | ALDH1A1 2221/4885HSD17B10 1602/4885ATAD2 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.